The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2023 | Real-world outcomes of brexu-cel in patients with R/R MCL
Swetha Kambhampati, MD, City of Hope, Duarte, CA, provides an update on an analysis of the real-world outcomes of brexucabtagene autoleucel (brexu-cel) in patients with relapsed/refractory mantle cell lymphoma (R/R MCL). The study analyzed high-risk, pretreated patients, including patients who had received prior BTK inhibitors, bendamustine, and stem cell transplantation (SCT). Real-world outcomes were comparable to the findings of ZUMA-2 (NCT02601313). Prior exposure to BTK inhibitors and bendamustine did not affect brexu-cel efficacy and safety, while prior autoHCT improved progression-free survival (PFS). Dr Kambhampati compares brexu-cel outcomes based on the number of prior lines of therapy and highlights the need for a longer follow-up. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
